Anti-trypanosomatid structure-based drug design - lessons learned from targeting the folate pathway
Introduction Trypanosomatidic parasitic infections in humans and animals caused by Trypanosoma brucei, Trypanosoma cruzi, and Leishmania species pose a significant health and economic burden in developing countries. There are few effective and accessible treatments for these diseases, and the existi...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
07 Oct 2022
|
| In: |
Expert opinion on drug discovery
Year: 2022, Jahrgang: 17, Heft: 9, Pages: 1029-1045 |
| ISSN: | 1746-045X |
| DOI: | 10.1080/17460441.2022.2113776 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/17460441.2022.2113776
|
| Verfasserangaben: | Joanna Panecka-Hofman, Ina Poehner, Rebecca C. Wade |
MARC
| LEADER | 00000caa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 1831210142 | ||
| 003 | DE-627 | ||
| 005 | 20230707003126.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230117s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/17460441.2022.2113776 |2 doi | |
| 035 | |a (DE-627)1831210142 | ||
| 035 | |a (DE-599)KXP1831210142 | ||
| 035 | |a (OCoLC)1389536280 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 32 |2 sdnb | ||
| 100 | 1 | |a Panecka-Hofman, Joanna |e VerfasserIn |0 (DE-588)1160563918 |0 (DE-627)1023833867 |0 (DE-576)50602069X |4 aut | |
| 245 | 1 | 0 | |a Anti-trypanosomatid structure-based drug design - lessons learned from targeting the folate pathway |c Joanna Panecka-Hofman, Ina Poehner, Rebecca C. Wade |
| 264 | 1 | |c 07 Oct 2022 | |
| 300 | |a 17 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 17.01.2023 | ||
| 520 | |a Introduction Trypanosomatidic parasitic infections in humans and animals caused by Trypanosoma brucei, Trypanosoma cruzi, and Leishmania species pose a significant health and economic burden in developing countries. There are few effective and accessible treatments for these diseases, and the existing therapies suffer from problems, such as parasite resistance and side effects. Structure-based drug design (SBDD) is one of the strategies that has been applied to discover new compounds targeting trypanosomatid-borne diseases.Areas covered We review the current literature (mostly over the last 5 years, searched in the PubMed database on 11 November 2021) on the application of structure-based drug design approaches to identify new anti-trypanosomatidic compounds that interfere with a validated target biochemical pathway, the trypanosomatid folate pathway.Expert opinion The application of structure-based drug design approaches to perturb the trypanosomatid folate pathway has successfully provided many new inhibitors with good selectivity profiles, most of which are natural products or their derivatives or have scaffolds of known drugs. However, the inhibitory effect against the target protein(s) often does not translate to anti-parasitic activity. Further progress is hampered by our incomplete understanding of parasite biology and biochemistry, which is necessary to complement SBDD in a multiparameter optimization approach to discovering selective anti-parasitic drugs. | ||
| 650 | 4 | |a Dihydrofolate reductase | |
| 650 | 4 | |a folate pathway | |
| 650 | 4 | |a molecular docking | |
| 650 | 4 | |a molecular dynamics | |
| 650 | 4 | |a pteridine reductase 1 | |
| 650 | 4 | |a structure-based drug design | |
| 650 | 4 | |a trypanosomatids | |
| 650 | 4 | |a virtual screening | |
| 700 | 1 | |a Poehner, Ina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wade, Rebecca C. |e VerfasserIn |0 (DE-588)102801774X |0 (DE-627)730136000 |0 (DE-576)276591402 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug discovery |d Abingdon : Taylor & Francis Group, 2006 |g 17(2022), 9, Seite 1029-1045 |h Online-Ressource |w (DE-627)525478329 |w (DE-600)2272966-5 |w (DE-576)302970312 |x 1746-045X |7 nnas |a Anti-trypanosomatid structure-based drug design - lessons learned from targeting the folate pathway |
| 773 | 1 | 8 | |g volume:17 |g year:2022 |g number:9 |g pages:1029-1045 |g extent:17 |a Anti-trypanosomatid structure-based drug design - lessons learned from targeting the folate pathway |
| 856 | 4 | 0 | |u https://doi.org/10.1080/17460441.2022.2113776 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230117 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 102801774X |a Wade, Rebecca C. |m 102801774X:Wade, Rebecca C. |d 140000 |d 160000 |e 140000PW102801774X |e 160000PW102801774X |k 0/140000/ |k 0/160000/ |p 3 |y j | ||
| 999 | |a KXP-PPN1831210142 |e 4248843234 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Anti-trypanosomatid structure-based drug design - lessons learned from targeting the folate pathway","title":"Anti-trypanosomatid structure-based drug design - lessons learned from targeting the folate pathway"}],"person":[{"display":"Panecka-Hofman, Joanna","family":"Panecka-Hofman","role":"aut","given":"Joanna"},{"given":"Ina","role":"aut","family":"Poehner","display":"Poehner, Ina"},{"display":"Wade, Rebecca C.","family":"Wade","role":"aut","given":"Rebecca C."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"17 S."}],"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"07 Oct 2022"}],"id":{"doi":["10.1080/17460441.2022.2113776"],"eki":["1831210142"]},"recId":"1831210142","name":{"displayForm":["Joanna Panecka-Hofman, Ina Poehner, Rebecca C. Wade"]},"note":["Gesehen am 17.01.2023"],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 11.04.16"],"physDesc":[{"extent":"Online-Ressource"}],"pubHistory":["1.2006 -"],"language":["eng"],"title":[{"title":"Expert opinion on drug discovery","title_sort":"Expert opinion on drug discovery"}],"recId":"525478329","disp":"Anti-trypanosomatid structure-based drug design - lessons learned from targeting the folate pathwayExpert opinion on drug discovery","id":{"issn":["1746-045X"],"zdb":["2272966-5"],"eki":["525478329"]},"origin":[{"publisherPlace":"Abingdon ; London","publisher":"Taylor & Francis Group ; Informa Healthcare","dateIssuedKey":"2006","dateIssuedDisp":"2006-"}],"part":{"issue":"9","year":"2022","extent":"17","text":"17(2022), 9, Seite 1029-1045","volume":"17","pages":"1029-1045"}}]} | ||
| SRT | |a PANECKAHOFANTITRYPAN0720 | ||